MedTrace Logo

Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors

NCT00071539 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-01-20

No results posted yet for this study

Summary

Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma.

Conditions

  • Recurrent Glioblastoma Multiforme

Interventions

DRUG

TP-38

Recombinant chimeric protein

DRUG

TP38

recombinant chimeric protein

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2006-01-31
Completion
2006-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00071539 on ClinicalTrials.gov